Johnson & Johnson reports a 95% four-year progression-free survival rate using the DARZALEX FASPRO®-based regimen in transplant-eligible, newly diagnosed multiple myeloma patients who achieved sustained MRD negativity.
Myeloma
GSK’s Blenrep combinations have received a positive opinion from the CHMP for treating relapsed/refractory multiple myeloma, backed by strong Phase III trial results showing improved survival outcomes.
Potentially Groundbreaking Treatment Could Delay or Prevent Progression to Full-Blown Myeloma.
GSK’s Blenrep combinations have been approved in Japan for treating relapsed or refractory multiple myeloma, following strong Phase III trial results demonstrating improved survival outcomes.
CellCentric has secured $120 million in Series C funding to accelerate clinical development of Inobrodib, its first-in-class oral p300/CBP inhibitor for treating multiple myeloma. The investment will support upcoming Phase II/III trials and global expansion.